Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement

Raymond Comenzo • 1 Jun 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone
VITAL

Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, explores the results of a study evaluating concurrent dual monoclonal antibody treatment with daratumumab and NEOD001, an anti-amyloid antibody, in systemic amyloid light-chain (AL) amyloidosis with cardiac involvement. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Raymond Comenzo

1:44
Bendamustine with dexamethasone in R/R systemic AL amyloidosis
Raymond Comenzo • 20 Jul 2020
2:54
Main results from the ANDROMEDA study
Raymond Comenzo • 1 Jun 2020
13:14
Amyloidosis: diagnosis and stem cell transplantation
Morie Gertz et al. • 14 Sep 2019
12:03
How will novel agents affect the amyloidosis population?
Morie Gertz et al. • 14 Sep 2019

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals